HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (6- (2,5- dimethoxyphenyl)- 4- oxo- 2- thioxo- 3,4- dihydropyrimidin- 1(2H)- yl)acetamide

a myeloperoxidase inhibitor; structure in first source

Also Known As:

PF-1355

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - 2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - 2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3

Experts

1.	Buckbinder, Leonard: 2 articles (12/2016 - 05/2015)
2.	Cortes, Christian: 2 articles (12/2016 - 05/2015)
3.	Ruggeri, Roger: 2 articles (12/2016 - 05/2015)
4.	Skoura, Athanasia: 2 articles (12/2016 - 05/2015)
5.	Zheng, Wei: 2 articles (12/2016 - 05/2015)
6.	Ali, Muhammad: 1 article (12/2016)
7.	Chen, John W: 1 article (12/2016)
8.	Courties, Gabriel: 1 article (12/2016)
9.	Dong, Anping: 1 article (12/2016)
10.	Hilgendorf, Ingo: 1 article (12/2016)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 12/01/2016 - "In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases."
2.	Vasculitis (Vasculitides) 05/01/2015 - "PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis."
3.	Myocarditis (Carditis) 11/14/2023 - "After treatment with PF-1355, compared to the myocarditis group, the left ventricular ejection fraction (LVEF) (73.58%±5.31% and 58.12%±3.19%, P<0.001) and left ventricular fraction shortening (LVFS) (39.78%±4.31% and 33.89%±2.19%, P<0.001) increased. "
4.	Myocardial Infarction 12/01/2016 - "PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. "
5.	Glomerulonephritis 05/01/2015 - "PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis."

Related Drugs and Biologics

1.	Peroxidase (Myeloperoxidase)
2.	Antigen-Antibody Complex (Immune Complex)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)